Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

This study is testing whether isatuximab (an antibody targeting myeloma cells) combined with lenalidomide (a standard maintenance drug) can eliminate residual multiple myeloma in patients who still have detectable cancer after an autologous stem cell transplant (a transplant using the patient's own stem cells). **You may be eligible if...** - You are over 18 years old - You have been diagnosed with multiple myeloma (not smoldering or plasma cell leukemia) - You completed an autologous stem cell transplant and still test positive for minimal residual disease (MRD positive) - You are willing to take blood clot prevention medication (aspirin, heparin, or similar) **You may NOT be eligible if...** - You have smoldering myeloma or plasma cell leukemia - You have significant amyloid-related organ damage - You are MRD-negative after transplant - You have health conditions that prevent use of lenalidomide or isatuximab Talk to your doctor to see if this trial is right for you.